Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer.
about
Advances in targeted therapies and new promising targets in esophageal cancerChemotherapy-Induced Constipation and Diarrhea: Pathophysiology, Current and Emerging TreatmentsA phase II study of oxaliplatin in combination with leucovorin and fluorouracil as first-line chemotherapy in patients with metastatic squamous cell carcinoma of esophagus.A phase II study of paclitaxel and nedaplatin as front-line chemotherapy in Chinese patients with metastatic esophageal squamous cell carcinomaPhase II Study of Irinotecan and Cisplatin Combination Chemotherapy in Metastatic, Unresectable Esophageal CancerRNA-seq reveals determinants of sensitivity to chemotherapy drugs in esophageal carcinoma cells.Current gene expression studies in esophageal carcinoma.Breast cancer resistance protein (BCRP) and excision repair cross complement-1 (ERCC1) expression in esophageal cancers and response to cisplatin and irinotecan based chemotherapy.Phase II study of weekly paclitaxel and capecitabine in patients with metastatic or recurrent esophageal squamous cell carcinoma.What is the "best" platinum: cisplatin, carboplatin, or oxaliplatin?Role of multidrug resistance protein 2 (MRP2) in chemoresistance and clinical outcome in oesophageal squamous cell carcinoma.Phase II Trial of Docetaxel and Carboplatin in Patients With Advanced Squamous Carcinoma of the Esophagus (E2298): A Trial of the Eastern Cooperative Oncology Group.Longitudinal Quality-of-Life Analysis of RTOG 94-05 (Int 0123):A Phase III Trial of Definitive Chemoradiotherapy for Esophageal Cancer.Symptom control.Phase I trial of weekly cisplatin, irinotecan and paclitaxel in patients with advanced gastrointestinal cancerCetuximab plus cisplatin, irinotecan, and thoracic radiotherapy as definitive treatment for locally advanced, unresectable esophageal cancer: a phase-II study of the SWOG (S0414)Neoadjuvant irinotecan, cisplatin, and concurrent radiation therapy with celecoxib for patients with locally advanced esophageal cancer.Recent developments in the systemic therapy of advanced gastroesophageal malignancies.Phase II trial of docetaxel, cisplatin and fluorouracil followed by carboplatin and radiotherapy in locally advanced oesophageal cancerInduction cisplatin-irinotecan followed by concurrent cisplatin-irinotecan and radiotherapy without surgery in oesophageal cancer: multicenter phase II FFCD trialDiffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer.Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer: final results of a phase II trial.Phase II study of bi-weekly administration of paclitaxel and cisplatin in patients with advanced oesophageal cancerIrinotecan, cisplatin and mitomycin in inoperable gastro-oesophageal and pancreatic cancers - a new active regimen.Prognostic factors for survival in patients with advanced oesophageal cancer treated with cisplatin-based combination chemotherapy.Phase I study of cisplatin, irinotecan, and epirubicin administered every 3 weeks in patients with advanced solid tumoursPhase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer.Feasibility of quality of life assessment in patients with upper gastrointestinal tract cancer.Preoperative cetuximab, irinotecan, cisplatin, and radiation therapy for patients with locally advanced esophageal cancerNew and emerging combination therapies for esophageal cancer.Improvement of cisplatin-related renal dysfunction by synthetic ghrelin: a prospective randomised phase II trialPhase II trial of docetaxel-irinotecan combination in advanced esophageal cancerTreatment and survival in a population-based sample of patients diagnosed with gastroesophageal adenocarcinomaWeekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancer.Patient-reported outcomes evaluating palliative radiotherapy and chemotherapy in patients with oesophageal cancer: a systematic review.Inhibition of pRB Pathway Differentially Modulates Apoptosis in Esophageal Cancer Cells.CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers.Integration of targeted agents in the neo-adjuvant treatment of gastro-esophageal cancers.Current management of esophageal squamous-cell carcinoma in Japan and other countries.Anti-EGFR-Targeted Therapy for Esophageal and Gastric Cancers: An Evolving Concept.
P2860
Q26825957-37FB5797-121B-4C0E-94B1-49A6F4878721Q28079705-714980DC-CDA6-4BB6-9658-98A7B6787A47Q33405628-06D6F1D9-2393-4058-900E-966BC862EBCCQ33410922-FEFE1B2E-B001-400F-8A4D-B5156B8E9564Q33434339-6D960A18-CF50-4E4B-B537-0AAED0CB1BE0Q33582964-19364B86-9FD6-45ED-8AEC-D36AA0DFDBCDQ33635353-4939B07C-2E88-477F-9FE7-BCE977157D86Q33947983-07999143-A429-455D-8E92-BA3B0025662AQ34010159-38802832-F80F-4F2C-AD9C-7F1418E24607Q34385440-F3941F61-A481-4C78-8931-C593290CAF2EQ34627891-4B3C59C2-4451-48EB-8CC5-67FEFF959875Q34758841-453E8214-8107-43F1-A751-FADCA528E9BEQ35030424-5DEABD55-474B-47F3-9895-6ACD548FD9ABQ35553856-200FA6A1-97E0-41F3-B6F7-779FD469CFD8Q35559881-9692C41E-4C3B-412E-A2D5-3A0A1FBD0584Q36055127-E8D42FD3-26A2-4C50-B723-7412D1199D67Q36076749-2E932607-E6D7-4F91-B66A-511A7C63B9D2Q36376439-4DC83E65-7485-483C-99E5-2F9096EED4DFQ36609800-C1F6E4F7-79DF-4897-9E5D-27876F98157CQ36611661-8C11E153-8880-4852-A268-D904F6F4DD21Q36614881-27605530-9825-479D-BA48-AD86680BE931Q36616002-56666491-4831-4F63-80A9-80B9905D30FDQ36644156-A4459C7A-7A29-4853-A5C9-63FE594777ABQ36646204-F6874FDD-7726-4284-8DFD-9C6831DA6A5CQ36648089-B23357BD-B0BD-403B-9909-F7329DDDA31EQ36648316-282515DF-244D-47DF-91E8-E9B680A46009Q36648325-1AE6FE57-091F-4AED-A88A-2EACEF53EAA6Q36671387-F5CFD0DF-9EDF-4C52-BC94-DD89F6409FCFQ36714384-B5D400AE-24F9-45CE-899F-42799E565AB2Q36996728-7AB6B90D-0AD3-4C04-82E7-6A1D6F4DED4BQ37174066-5C2F6E91-50D0-4D57-8CB6-E24B40E216C7Q37235047-8CAA6C42-809E-4334-9DAE-980FFFEF6BCAQ37267270-8D200A34-19E8-4ABD-86AF-527DCDF5CA65Q37321790-8F6CC404-E7BB-478A-8F60-2F374E810EC9Q38063344-C0F7470E-758A-4952-8633-1F86A9D69E1FQ38666834-A907B056-CE72-4922-A603-F9FCABD8C18CQ38844897-940A908D-2FF9-47B8-AA18-066E843E601BQ39933959-F55A0B0C-8B0F-4578-8CE5-B7D3B04D0346Q42113341-9210D1DA-8FAB-4C9B-9E0F-8048EAB70554Q42119902-9AC1D107-F6F6-4E2F-AB71-7C82DEA1A3D9
P2860
Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh
1999年學術文章
@zh-hant
name
Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer.
@en
Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer.
@nl
type
label
Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer.
@en
Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer.
@nl
prefLabel
Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer.
@en
Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer.
@nl
P2093
P1476
Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer.
@en
P2093
A Kornblith
D P Kelsen
E O'Reilly
G Gonzalez
G Schwartz
P Enzinger
P304
P356
10.1200/JCO.1999.17.10.3270
P407
P577
1999-10-01T00:00:00Z